Articles On Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals (ASX:RCE) has successfully filled its coffers ahead of its Phase III clinical trials in Indonesia and Australia, with the company this week landing “firm commitments” to place the full shortfall in its capital raise....

Recce entitlement offer shortfall placed to existing institutional and sophisticated investors, raising $7.4 million Shortfall placement concludes Recce’s $15.8 million capital raising to support phase III clinical trials in Indonesia and...

Recce secures patent acceptance in China for anti-infectives Acceptance strengthens the company’s global patent portfolio Recce tackling global health problem of antibiotic-resistant superbugs   Special Report: Recce Pharmaceuticals has...

ASX health stocks up 0.57% over past week, while the broader market is up 0.35%  Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF’s woes continue with company downgrading FY25 blami...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Airtasker ((ART...

ASX falls almost 1pc on Monday after setting new 20-day high last week Sectors in the red right across the board Falling oil price weighs heavily on Energy sector, down more than 2.8pc   An eighth day of gains just wasn’t to be for the AS...

Highlights US markets extend gains, driven by trade optimism and strong corporate earnings. The Australian market remains stable, with financial and materials sectors seeing limited movement. Local focus turns to CPI data, w...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Recce receives HREC approval to expand its Phase II clinical trial for diabetic foot infections Approval allows up to 20 additional patients access to access its R327G treatment Follows recently released positive Phase II clinical trial d...

Recce Pharmaceuticals (ASX:RCE) has received a boost to the development of its topical gel for the treatment of diabetic foot infections, as 20 more patients with the condition are added to its Phase II clinical trial of the product, R327G....

Oil prices lift almost 2pc, boosting energy sector Gold reaches all-new highs of $US3,332 per ounce, pushing ASX Gold index higher Strength in rare earths lifts small cap index and materials sector   Energy and resources stocks have been...

Highlights: Recce Pharmaceuticals initiates a two-part capital raise to support advanced clinical trials Funding allocated to clinical programs focused on diabetic foot and bacterial skin infections Trials to be conducted ac...

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor and $10.8M Entitlement Offer to shareholders....

Funding to support Phase III clinical trials for diabetic foot infections and acute bacterial skin and skin structure infections Private Australian-based investor has subscribed for $5 million shares via a placement A$10.8 million entitlem...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

Superbug-buster Recce has bucked the trend by targeting Indonesia as the host of its planned phase III diabetic foot ulcer trial Recce’s synthetic antibiotic candidate seeks to overcome the problem of antimicrobial resistance A local phase...

ASX slides again, seven losses in eight days Copper tariff talk spooks miners, Rio and BHP down Woolies, Platinum, and Flight Centre also take a hit   It was another rocky ride for local stocks today, with the ASX 200 benchmark down by 0....

Banks drag as Bendigo, Westpac slump Star Entertainment Group jumps on $650m refinancing Jack Ma’s return sparks tech rally in China   The ASX retreated by about 0.37% from Friday’s record high, with banks pulling the market down on Monda...

Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections. The company designed t...

A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections Recce said objectives exceeded with a 93% primary efficacy endpoint achieved f...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute Bacterial Skin and Skin Structure Infections, including patients with Diabetic Foot Infections, with a primary efficacy...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 has been up 0.5% at 8,445 points. Just after the local bourse opened, Trump says the U.S. is seriously considering tariffs on China due to the alleged production and distribution of fentanyl. IT has been the best performing...

ASX reverses after Trump’s tariff threat sends jitters Bitcoin drops as Trump’s policies remain unclear Hub24 shines, Santos slumps after project delay   After an upbeat start to the day, the S&P/ASX 200 Index, which had surged as muc...

Recce Pharmaceuticals Ltd (ASX:RCE) has seen its share price move up more than 1% on Tuesday’s news that the company successfully dosed all 30 participants in its Phase II clinical trial of a gel to treat skin infections. The trial – who...

RCE has dosed all patients in phase II trial of R327G treatment for skin infections Company says market valued at US$26bn globally Results pending ahead of planned phase III trial   Special Report: Recce Pharmaceuticals has wrapped up dos...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Airtasker ((ART...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Sarah Hughan explores Recce Pharmaceuticals (ASX:RCE) and a series of succes...

Sydney-based Recce Pharmaceutical Ltd (ASX:RCE) has reached a landmark stage in its bid to commercialise a topical gel that would treat diabetic foot infections (DFIs), gaining approval for a Phase 3 trial in Indonesia to assess the gel in...

ASX drops as Trump’s tariff threat rattles markets Bluescope and Reece rise amid energy and bank sell-off EML Payments jumps after strong earnings report   The ASX closed in the red on Tuesday, down by 0.45% after being dragged down by a...

Recce Pharmaceuticals Ltd (ASX:RCE) has ticked off completion of all patents for two of its key anti-infectives, with the Australian Patent Office granting ‘Patent Family 3’ status to RECCE 327 (R327) and RECCE 529 (R529). The latest pat...

World Antimicrobial Resistance Awareness Week aims to put a spotlight on growing threat of antimicrobial resistance  Recce is tackling the global health problem of antibiotic-resistant superbugs with its new class of synthetic anti-infecti...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Recce Pharmaceuticals (ASX:RCE) has received a $6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24. This receipt was used to repay advances from Endpoints Capital reflectin...

ASX starts week lower with mining stocks under pressure Resolute mining plunges after CEO detained in Mali Bitcoin surges past US$81k as Trump’s win fuels optimism   The ASX had a rough start to the week, with mining stocks dragging the m...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals’ (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of i...

The ASX200 closed down 0.4% at 8,131 points. The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going t...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure infections The study is designed to evaluate the efficacy of topical gel RECCE® 327 (R327G) It is designed to treat dia...

Non-DSMB unanimously agree Recce’s topical gel R327G is safe and well-tolerated in patients with acute bacterial skin and skin-structure infections R327G demonstrates highly encouraging efficacy results with all patients completing treatme...

  ASX closes  higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans   The ASX closed 0.13% higher on Wednesday, thanks...

Recce Pharmaceuticals Ltd (ASX:RCE) has reached the halfway mark in dosing participants in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The company has dosed 15 patients in the trial so far, wh...

Echo IQ shares soar after the FDA approves its aortic stenosis diagnosis. Pacific Edge’s cancer diagnostic revenues hold up despite US reimbursement doubts Recce Pharmaceuticals reaches halfway mark in phase II germ-busting trial   Health...

For those not regular watchers of the ASX biotech sector, it’s worth noting Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. Recce is developing its flagship patented next-gen anti-infective, R327, with clinical results so f...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham. Cracking the...

Southeast Asia presents growth for ASX health stocks with rising aging population and growing middle class EZZ has started selling EAORON branded products in Vietnam and signed Australian Open sponsorship deal  Recce has signed a MoU with...

Antimicrobial resistance is among the most significant threats to public health and development, says WHO Recce Pharmaceuticals is tackling the global health problem of antibiotic-resistant superbugs It has a military reconnaissance appro...

The ASX200 has hit a fresh all time high of 8,035 points in buoyant Monday trade with the market up 0.8% heading into 1pm. Investors are speculating the Federal Reserve in the United States could launch its rate cutting cycle with a 50 b...

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department o...